Quantcast
Home > Quotes > ONS

Oncobiologics, Inc. Common Stock (ONS) Quote & Summary Data

ONS 
$0.735
*  
0.015
2.08%
Get ONS Alerts
*Delayed - data as of Nov. 19, 2018 15:00 ET  -  Find a broker to begin trading ONS now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ONS Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.725 / $ 0.735
1 Year Target
Today's High / Low
$ 0.735 / $ 0.7001
Share Volume
20,142
50 Day Avg. Daily Volume
45,622
Previous Close
$ 0.72
52 Week High / Low
$ 1.53 / $ 0.572
Market Cap
53,065,874
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.78

Intraday Chart

Shares Traded

Share Volume:
20,142
50 Day Avg. Daily Volume:
45,622

Trading Range

The current last sale of $0.735 is 28.50% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.735 $ 1.53
 Low: $ 0.7001 $ 0.572

Company Description (as filed with the SEC)

We are a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies, or mAbs, in the disease areas of immunology and oncology. A mAb is a type of protein that is produced by a single clone of cells or cell line and made to bind to a specific substance in the body. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team's biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony Platform.  ... More ...  


Risk Grade

Where does ONS fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 0.701
Open Date:
Nov. 19, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x